Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368538 | 1.00 | CHKA (0.40) | CHKATP53SIGMAR1CALM1ALDH1A1 | |
| SCHEMBL9318596 | 0.98 | TP53 (0.42) | CHKATP53SIGMAR1CALM1ALDH1A1 | |
| SCHEMBL6549159 | 0.87 | TP53 (0.46) | CHKATP53SIGMAR1CALM1ALDH1A1 | |
| SCHEMBL5100518 | 0.79 | TP53 (0.39) | CHKATP53SIGMAR1CALM1ALDH1A1 | |
| SCHEMBL11155177 | 0.77 | SIGMAR1 (0.44) | TP53SIGMAR1CALM1ALDH1A1TSHR | |
| SCHEMBL27609076 | 0.74 | ACHE (0.47) | TP53SIGMAR1ALDH1A1HTT | |
| SCHEMBL348590 | 0.74 | ALDH1A1 (0.39) | TP53ALDH1A1TSHR | |
| SCHEMBL349052 | 0.71 | GBA1 (0.39) | ALDH1A1SMN1; SMN2TSHRTDP1 | |
| SCHEMBL7283642 | 0.70 | CHKA (0.36) | CHKATP53SIGMAR1CALM1ALDH1A1 | |
| SCHEMBL11347488 | 0.69 | SLC18A3 (0.47) | SIGMAR1ALDH1A1LMNAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0238211-B1 | Dihydropyridines, process for their preparation and their use as medicaments | GLAXO SPA (IT) | 1994-01-12 | — | — | EP | claimed |
| US-5051432-A | Heterocyclic 1,4 dihydropyridine derivatives | GLAXO, S.P.A. (IT) | 1991-09-24 | — | — | US | claimed |
| EP-0238211-A2 | Dihydropyridines, process for their preparation and their use as medicaments | GLAXO S.p.A. (IT) | 1987-09-23 | — | — | EP | claimed |
| EP-2421874-B1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2421874-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | Evonik Degussa GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121873-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
| EP-0238211-B1 | Dihydropyridines, process for their preparation and their use as medicaments | GLAXO SPA (IT) | 1994-01-12 | — | — | EP | disclosed |
| US-5051432-A | Heterocyclic 1,4 dihydropyridine derivatives | GLAXO, S.P.A. (IT) | 1991-09-24 | — | — | US | disclosed |
| EP-0238211-A2 | Dihydropyridines, process for their preparation and their use as medicaments | GLAXO S.p.A. (IT) | 1987-09-23 | — | — | EP | disclosed |
| EP-0054748-B1 | PROCESS FOR THE PREPARATION OF AQUEOUS SOLUTIONS OF CATIONIC ORGANOSILICIUM COMPOUNDS | Degussa Aktiengesellschaft (DE) | 1984-09-26 | — | — | EP | disclosed |
| EP-0054748-A2 | Process for the preparation of aqueous solutions of cationic organosilicium compounds | Degussa Aktiengesellschaft (DE) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | MKI67, HRAS, VHL | CHKA 2448/4885TP53 12/4885SIGMAR1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.